Outcome of single agent generic gemcitabine in platinum-resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma.
Single original gemcitabine is commonly used as salvage treatment in platinum-resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma (PPA) with a satisfactory outcome. However, efficacy data fro this regimen are limited. We therefore conducted a retrospective study to...
Saved in:
Main Authors: | Suprasert P., Cheewakriangkrai C., Manopunya M. |
---|---|
Format: | Article |
Language: | English |
Published: |
2014
|
Online Access: | http://www.scopus.com/inward/record.url?eid=2-s2.0-84866463864&partnerID=40&md5=bb053e41b807ea92693b51c6a89e39ce http://cmuir.cmu.ac.th/handle/6653943832/3973 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
Language: | English |
Similar Items
-
Outcome of single agent generic gemcitabine in platinum-resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma
by: Suprasert P., et al.
Published: (2014) -
Outcome of single agent generic gemcitabine in platinum- resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma
by: Suprasert P., et al.
Published: (2014) -
Outcome of single agent generic gemcitabine in platinum-resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma
by: Prapaporn Suprasert, et al.
Published: (2018) -
Outcomes with single agent LIPO-DOX in platinum-resistant ovarian and fallopian tube cancers and primary peritoneal adenocarcinoma - Chiang Mai University Hospital experience
by: Prapaporn Suprasert, et al.
Published: (2018) -
Outcomes with single agent LIPO-DOX in platinum-resistant ovarian and fallopian tube cancers and primary peritoneal adenocarcinoma - Chiang Mai University Hospital experience
by: Prapaporn Suprasert, et al.
Published: (2018)